Rashmi started her career on Wall Street with time spent in both convertible bonds sales and trading at Goldman Sachs and structured derivative products at Lehman Brothers. She left to form her own healthcare consulting practice, and spent over a decade advising a wide range of clients from large university hospitals to start-ups on business and financial strategies. Her role included taking interim COO and CFO positions for clients managing periods of high growth or other business transitions.
In 2007, she began splitting her time between the US and Asia (China, Indonesia, and Singapore) and expanded her consulting business to include advisory on business communications strategies and global thought leadership. Prior to joining The Economist Group, she was Head of Strategic Planning at Weber Shandwick, a global communications and PR firm, in Singapore.
Rashmi holds a Bachelors in International Affairs from Johns Hopkins University and a Masters in International Affairs from Columbia University with a concentration in International Finance and Banking.
《沉默的代价:亚洲地区心血管疾病现状》是经济学人智库和 EIU Healthcare 所作的报告。它提供了关于心血管疾病危险因素经济影响的研究，研究范围包括以下亚洲市场：中国、澳大利亚、中国香港、日本、新加坡、韩国、中国台湾和泰国。
研究着重探讨了缺血性心脏病（IHD）和中风所造成的损失。缺血性心脏病，又称冠心病（coronary heart disease，CHD）或冠状动脉疾病，是指负责为心肌供血的心脏动脉（冠状动脉）狭窄而导致的心脏疾病。这可能导致稳定性心绞痛、不稳定性心绞痛、心肌梗死或心脏病发作，以及心脏性猝死。中风的主要特征则是大脑局部突然失去血液供应，可能由脑血管阻塞、大出血或血栓所引起。
本项研究对既有的心血管疾病研究进行了循证综述，并进行了一系列基于专家访谈的初步研究。
本报告关键信息如下：
white paper
The Cost of Silence: Cardiovascular disease in Asia is a report by The Economist Intelligence Unit and EIU
white paper
循環器疾患(CVD
infographic
Cardiovascular diseases levy a substantial financial toll on individuals, their households and the public finances. These include the costs of hospital treatment, long-term disease management and recurring incidence of heart attacks and stroke. They also include the costs of functional impairment and knock-on costs as families may lose breadwinners or have to withdraw other family members from the workforce to care for a CVD patient. Governments also lose tax revenue due to early retirement and mortality, and can be forced to reallocate public finances from other budgets to maintain an accessible healthcare system in the face of rising costs.
As such, there is a need for more awareness of the ways in which people should actively work to reduce their CVD risk. There is also a need for more primary and secondary preventative support from health agencies, policymakers and nongovernmental groups.
To inform the decisions and strategies of these stakeholders, The Economist Intelligence Unit and EIU Healthcare, its healthcare subsidiary, have conducted a study of the prevalence and costs of the top four modifiable risk factors that contribute to CVDs across the Asian markets of China, Australia, Hong Kong, Japan, Singapore, South Korea, Taiwan and Thailand.
Download the report to learn more.
The need to get better value from healthcare investment has never been more important as ageing populations and increasing numbers of people with multiple chronic conditions force governments to make limited financial resources go further.
These pressures, along with a greater focus on patient-centred care, have raised the profile of VBHC, especially in European healthcare systems. Sweden, with its highly comprehensive and egalitarian healthcare system, has been a leader in implementing VBHC from the beginning, a fact that was underscored in a 2016 global assessment of VBHC published by The Economist Intelligence Unit.
This paper looks at the ways in which Sweden has implemented VBHC, the areas in which it has faced obstacles and the lessons that it can teach other countries and health systems looking to improve the value of their own healthcare investments.
